Document registry — page 25
Every document the Institute has published, 1,639 in total, with its identifier, type, certainty rating and review date.
Documents
-
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low21 Jan 2025 -
Single-arm open-label, phase 2 study of Survodutide in obesity over open-label extension of the parent trial. The Institute holds no reported primary result for this…
Very low20 Jan 2025 -
Steatotic liver disease with histological evidence of hepatocyte ballooning and lobular inflammation occurring in the context of at least one cardiometabolic risk…
18 Jan 2025 -
Consultation on the draft of this intervention review, which registers the question: In adults with type 2 diabetes and chronic kidney disease, what is the effect of a…
17 Jan 2025 -
Dual GIP and GLP-1 receptor agonist (acylated). Tirzepatide engages both incretin receptors from a single molecule. GLP-1 receptor agonism reproduces the insulinotropic, glucagonostatic, gastric…
High16 Jan 2025 -
Peptides, SARMs, injectable oils and raw materials. Established life-science reagent operation.
15 Jan 2025 -
Consultation on the search-strategy template used across the synthesis series: the databases searched, the structure of the strategy, the handling of registry records…
13 Jan 2025 -
Randomised, double-blind, placebo-controlled, phase 2 study of Maridebart cafraglutide in obesity randomising 592 participants over 52 weeks. Primary result: Mean change…
Low12 Jan 2025 -
In the population defined for cognitive performance and neuroprotection, what is the incidence of adverse events leading to discontinuation with Semax compared with its…
Very low11 Jan 2025 -
Consultation on the structure of the document registry: the identifier scheme, the fields carried for every document, and the way a superseded document is represented…
10 Jan 2025 -
Restoration of epithelial and dermal integrity following injury, assessed by closure rate, area reduction and scar quality.
08 Jan 2025 -
Consultation on the draft of this methodological review, which registers the question: For neuropeptides holding a national marketing registration outside the…
06 Jan 2025 -
Consultation on how the Institute should label a programme record it has constructed by grouping trials, as distinct from a programme as defined by its sponsor. The…
05 Jan 2025 -
Consultation on the draft of this safety review, which registers the question: Do incretin-based therapies increase the incidence of acute pancreatitis?
04 Jan 2025 -
Randomised, double-blind, placebo-controlled study of Semax in cognition over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low01 Jan 2025 -
Consultation on the draft monograph for Semaglutide, oral, which the assessment committee released for public comment before ratification. The draft grades the…
30 Dec 2024 -
Consultation on the draft of CEI-MS-10, which specifies the performance a determination must achieve for content and states what the resulting figure does not establish…
28 Dec 2024 -
In the population defined for cognitive performance and neuroprotection, what is the effect of Semax compared with the comparator used in its contributing trials on the…
Very low26 Dec 2024 -
Record of documents ratified in the 2024 Q4 assessment cycle.
22 Dec 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of BPC-157 in mucosal barrier over not recorded. Primary result: The Institute has identified references to a…
15 Dec 2024 -
In the population defined for growth hormone deficiency and growth-hormone secretagogue pharmacology, what is the effect of CJC-1295 compared with the comparator used in…
Low12 Dec 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in sleep apnoea and obesity over 52 weeks. Primary result: Substantial reduction in the…
High11 Dec 2024 -
Consultation on the draft monograph for Survodutide, which the assessment committee released for public comment before ratification. The draft grades the compound's…
10 Dec 2024 -
Persistent reduction in estimated glomerular filtration rate or persistent albuminuria in the context of type 2 diabetes, staged by eGFR and urine albumin-to-creatinine…
10 Dec 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Survodutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low09 Dec 2024 -
In the population defined for hiv-associated lipodystrophy and excess visceral adiposity, what is the incidence of adverse events leading to discontinuation with…
Moderate08 Dec 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Survodutide in mash randomising 295 participants over 48 weeks. Primary result: Improvement in 62 % to 83…
Low08 Dec 2024 -
Consultation on the draft of this intervention review, which registers the question: In adults with obesity and moderate to severe obstructive sleep apnoea, what is the…
05 Dec 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of BPC-157 in mucosal barrier over as stated in the parent protocol. The Institute holds no reported primary…
Very low05 Dec 2024 -
Non-selective melanocortin receptor agonist (cyclic heptapeptide). Melanotan-II is a potent non-selective melanocortin receptor agonist. MC1R agonism stimulates eumelanin synthesis in melanocytes, producing…
Very low02 Dec 2024 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the incidence of adverse events leading to…
High27 Nov 2024 -
Observational study of Semax in cognition over not recorded. Primary result: Registered in the Russian Federation on a national evidence base the Institute has not been…
20 Nov 2024 -
Phase 1 ascending dose, phase 1 study of Epithalon in ageing over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low20 Nov 2024 -
Observational study of Selank in cognition over not recorded. Primary result: As for semax. The Institute records the absence of a retrievable controlled trial.
15 Nov 2024 -
Consultation on the draft monograph for Thymosin alpha-1, which the assessment committee released for public comment before ratification. The draft grades the compound's…
13 Nov 2024 -
Synthesis: Maridebart cafraglutide in obesity and overweight in adults: effect on the anchor outcome
In the population defined for obesity and overweight in adults, what is the effect of Maridebart cafraglutide compared with the comparator used in its contributing…
Low13 Nov 2024 -
Peptides, SARMs, injectables and raw materials. 388 published third-party test reports at the date of assessment.
12 Nov 2024 -
Diagnostic accuracy study of Sermorelin in gh axis over single test. Primary result: Formerly marketed as a diagnostic agent; withdrawn for commercial reasons.
Moderate11 Nov 2024 -
In the population defined for obesity and overweight in adults, is the effect of Orforglipron maintained across the full duration of the contributing trials?
Moderate09 Nov 2024 -
Peptides, oligonucleotides, SARMs, injectable oils and raw materials. 350+ catalogue lines.
09 Nov 2024
page 25 of 41